source
- Entrada Therapeutics shares plunge after Duchenne trial shows modest dystrophin increaseEntrada Therapeutics reported early data from a Phase 1/2 study of its RNA‑based therapy ENTR‑601‑44 for Duchenne muscular dystrophy, noting favorable safety and tolerability. The trial showed a d…
- Political appointee stalls Sanofi drug approval, raising concerns about FDA interferenceSTAT's D.C. Diagnosis newsletter reports that a political appointee is impeding the approval of a Sanofi drug, suggesting direct political interference at the FDA. The article notes that the appoi…